Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Is waiting safe for AFib? new study tests delayed treatment

NCT ID NCT04267159

Disease control Sponsor: Tampere University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether it's safe to wait 5-9 days before treating a sudden episode of atrial fibrillation or flutter, instead of treating it right away in the emergency room. About 500 patients who are stable enough to go home will be randomly assigned to either immediate treatment or delayed treatment at a clinic visit. The goal is to see if both approaches are equally safe and effective at restoring normal heart rhythm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients presenting with acute (\<48hours) atrial fibrillation or atrial flutter to ER * Planned acute rhythm control for the arrhythmia by the attending physician in ER * Good perceived health as assessed by attending physician in ER * Resting heart rate 110bpm or lower before or after adequate rate control therapy Exclusion Criteria: * Haemodynamically stable (mean arterial pressure above 60mmHg) * Need for acute restoration of sinus rhythm due to some other somatic cause * No other major complicating acute illness (e.g. decompensated HF or acute MI) * Anticoagulation not safe * Mechanical heart valve or mitral stenosis * The need for prolonged (\>24h) hospitalization due to any cause * Exceptionally high risk for thromboembolic events (e.g. history of thromboembolic stroke regardless of adequate anticoagulation) * Transesophageal echocardiography contraindicated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial flutter

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Atrial flutter

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Central Finland Central Hospital

    RECRUITING

    Jyväskylä, Central Finland, Finland

  • Kanta-Häme Central Hospital

    RECRUITING

    Hämeenlinna, Kanta-Häme, Finland

  • Päijät-Häme Central Hospital

    NOT_YET_RECRUITING

    Lahti, Paijat-Hame Region, Finland

  • Tampere University Hospital

    RECRUITING

    Tampere, Pirkanmaa, 03220, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.